Therapy-Induced Neutropenia and Poor Prognosis in Patients with Locally Advanced Esophageal Cancer Who Underwent Concurrent Chemoradiotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil.

ABSTRACT: Background: The prognostic impact of therapy-induced neutropenia in patients receiving definitive chemoradiotherapy for locally advanced thoracic esophageal cancer (EC) remains inadequately characterized. This study aimed to evaluate the association between grade 3-4 neutropenia and survival outcomes following docetaxel-cisplatin-5-fluorouracil (DCF) combined with radiotherapy (DCF-RT). Methods: Fifty patients with locally advanced thoracic EC were included in this study. Chemotherapy consisted of intravenous docetaxel at 50 mg/m² (day 1), CDDP at 60 mg/m² (day 1), and 5-FU at 600 mg/m² (days 1 to 4), administered every four weeks for two cycles in combination with radiotherapy (60 Gy in 30 fractions). Toxicities were assessed using the Common

SUBMITTER: Sakai M 

PROVIDER: S-EPMC12785004 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature